In recent years genetic testing has been introduced...
Scaling up can be a challenge; know the processes and tools for a successful transition....
In 2005 I had raised a question about Batch or a Continuous Process: A Choice. At that time it...
There has always been much hand-wringing and shouting regarding the costs of new medications. Most of this comes from people outside the industry – politicians, public health advocates, and a smattering of those that just like to hear themselves talk.
Humans are a strange lot. We are more than willing to believe just about any product claim in the hopes that an easy solution to our problem can be found inside a pill, tablet or liquid.
In an ideal world, OpenFDA could usher in a world of new and improved tools and products that would improve patient safety and adherence, increase physician awareness of drug safety dangers, assist healthcare decision makers who are driving prescribing behavior with better decision support, and lower the overall cost of care by reducing avoidable side effects. But we don’t live in an ideal world.
Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.
If you’re currently planning on implementing a Manufacturing Execution System (MES) or other applications in the Manufacturing Operations Management (MOM) space, you may think you have all the shop-floor areas and situations that still use manual, paper-based processes identified, but this may not necessarily be the case.
There are times when you hold new technology in your hands and realize that you are looking at something special, something that will, to use an oft-cited cliché, be a “game-changer.”
Chances are, an increased rate of production response to changes in supply and demand is high on your operational wish-list. And you’re not alone. When it comes to increased agility, it’s hard to argue there’s such a thing as too fast, and even small improvements in the ability to quickly ramp production up or down can translate to significant long-term bottom-line gains.
While British attention in the Pfizer-AstraZeneca takeover battle has been focused on clashes between MPs and Pfizer chief executive Ian Read, events have been unfolding across the Atlantic which could have an infinitely greater bearing on where the pharma giant eventually conducts its business.
It’s 2014, and that means there are a handful of ways you could be perusing this and any other sentences on your reading queue, daily to-do list, etc. While it’s certainly possible you printed it out, it’s far more likely that you’re viewing it on your desktop or laptop or, increasingly from smaller mobile devices like tablets or even your smartphone, perhaps with your window for your favorite game app temporarily minimized.
Last week there was much excitement and press coverage regarding the results of a Phase III drug study for pancreatic cancer. The company that developed the drug issued a press release, the Pancreatic Cancer Action Network issued a press release – both extolling the new drug’s ability to increase the life expectancy of those with pancreatic cancer.
Regardless of which stage a product is entering the pharmaceutical production line, keeping the work flow moving seamlessly without sacrificing safety and quality is paramount to any operation. Enter the compact workstation.
While smart companies consider the final packaging of their product concurrently with the development of the product, sometimes it’s evident that even the smartest companies fail to consider every aspect of their packaging when it finally comes in contact with the consumer.
Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?
The current buzz-term “Big Data” may be slightly misleading in the strictest sense. The concept is nothing new. Most manufacturers are quite accustomed to having “big,” some might say huge, amounts of data flowing throughout their organizations, but have historically lacked the context that gives that data actionable meaning—giving birth to the oft used phrase, “data rich, but information poor.”
The controversy over vaccinations is back in the spotlight, after a Colorado bill passed tightening the loophole that allows parents to choose not to vaccinate, and actress Kristen Cavalarri spoke out against vaccinations claiming a connection with autism. What's more frightening is the frequency of outbreaks of diseases we thought we'd eradicated.